These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33439755)

  • 1. The Effects of Antiglaucoma Ophthalmic Solutions on the Cornea Revealed by a Corneal Electrical Resistance Device.
    Takeda N; Fukuda M; Sasaki H; Sugiyama K
    J Ocul Pharmacol Ther; 2021 Mar; 37(2):97-103. PubMed ID: 33439755
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide.
    Fukuda M; Takeda N; Shibata S; Shibata N; Shibata T; Sugiyama K; Sasaki H
    Eur J Pharmacol; 2016 Sep; 787():43-6. PubMed ID: 27181069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops.
    Mohamed YH; Uematsu M; Onizuka N; Ueki R; Inoue D; Fujikawa A; Sasaki H; Kitaoka T
    Curr Eye Res; 2016 Oct; 41(10):1326-1330. PubMed ID: 27002346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corneal and conjunctival changes caused by commonly used glaucoma medications.
    Noecker RJ; Herrygers LA; Anwaruddin R
    Cornea; 2004 Jul; 23(5):490-6. PubMed ID: 15220734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide.
    Fukuda M; Takeda N; Ishida H; Seki Y; Shibata N; Takahashi N; Sugiyama K; Kubo E; Sasaki H
    J Ocul Pharmacol Ther; 2022; 38(1):85-91. PubMed ID: 34936495
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride.
    Ayaki M; Iwasawa A; Niwano Y
    Biocontrol Sci; 2012; 17(3):115-20. PubMed ID: 23007102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
    Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
    Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns.
    Okada Y
    Cornea; 2007 Oct; 26(9 Suppl 1):S46-54. PubMed ID: 17881916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops.
    Ayaki M; Iwasawa A; Niwano Y
    Biocontrol Sci; 2012; 17(3):121-8. PubMed ID: 23007103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)].
    Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y
    Yakugaku Zasshi; 2011; 131(6):985-91. PubMed ID: 21628988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops.
    Inoue D; Mohamed YH; Uematsu M; Kitaoka T
    Cutan Ocul Toxicol; 2020 Jun; 39(2):158-164. PubMed ID: 32295438
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
    Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
    Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes.
    Fukuda M; Sasaki H
    J Ocul Pharmacol Ther; 2015 Feb; 31(1):57-60. PubMed ID: 25303115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of combination glaucoma medications on ocular surface epithelial cells.
    Ammar DA; Kahook MY
    Adv Ther; 2009 Oct; 26(10):970-5. PubMed ID: 19921496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
    Liang H; Baudouin C; Pauly A; Brignole-Baudouin F
    Br J Ophthalmol; 2008 Sep; 92(9):1275-82. PubMed ID: 18723745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in corneal damage due to benzalkonium chloride by the addition of sericin into timolol maleate eye drops.
    Nagai N; Ito Y; Okamoto N; Shimomura Y
    J Oleo Sci; 2013; 62(3):159-66. PubMed ID: 23470443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
    Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
    Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride.
    Ichijima H; Petroll WM; Jester JV; Cavanagh HD
    Cornea; 1992 May; 11(3):221-5. PubMed ID: 1587129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.